Skip to main content
SpringerLink
Log in

Niedrigmaligne Non-Hodgkin-Lymphome beim alten und geriatrischen Patienten

  • Living reference work entry
  • First Online:
Geriatrische Onkologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 120 Accesses

Zusammenfassung

Indolente bzw. niedrigmaligne Non-Hodgkin-Lymphome machen 35–40 % aller Non-Hodgkin-Lymphome aus, unterscheiden sich gegenüber den hochmalignen Lymphomen durch einen häufig über Jahre dauernden nicht aggressiven Verlauf. Der häufigste Subtyp der indolenten Lymphome ist das follikuläre Lymphom. Dieses stellt den zweithäufigsten Subtyp der nodalen lymphoiden Malignome in Europa dar. Die jährliche Inzidenz liegt bei ca. 5–7/100000 (Dreyling et al. 2014). Die verschiedenen Subtypen der indolenten Lymphome unterscheiden sich häufig nur in Nuancen, der Verlauf sowie die Behandlungsgrundsätze ähneln sich. Wir möchten uns daher bei diesem Artikel exemplarisch auf das follikuläre Lymphom, welches 60 % der indolenten NHL-Patienten ausmacht, konzentrieren.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Literatur

  • Ardeshna KM, Smith P, Norton A et al (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362(9383):516–522

    Article  CAS  PubMed  Google Scholar 

  • Ardeshna KM, Qian W, Smith P et al (2014) Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol 15(4):424–435. doi:10.1016/S1470-2045(14)70027-0. Epub 2014 Mar 4

    Article  CAS  PubMed  Google Scholar 

  • Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U, Ladetto M, ESMO Guidelines Working Group (2014) Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii76–iii82

    Article  PubMed  Google Scholar 

  • Federico M, Bellei M, Marcheselli L et al (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27(27):4555–4562

    Article  PubMed  Google Scholar 

  • Feuerlein K, Zucca E, Ghielmini M (2009) First-line treatment of follicular lymphoma: a patient-oriented algorithm. Leuk Lymphoma 50:325–334

    Article  CAS  PubMed  Google Scholar 

  • Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O’Brien SM (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370(11):997–1007

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA (2014) PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370(11):1008–1018

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • DGHO Onkopedia-Leitlinie (2017). https://www.onkopedia.com/de/onkopedia/guidelines/follikulaeres-lymphom/@@view/html/index.html. Zugegriffen im Mai 2017

  • O’Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol 23(4):676–684

    Article  PubMed  Google Scholar 

  • Pugh TJ, Ballonoff A, Newman F, Rabinovitch R (2010) Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a surveillance, epidemiology, and end results database analysis. Cancer 116(16):3843–3851

    Article  PubMed  Google Scholar 

  • Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W, Study group indolent Lymphomas (StiL) (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203–1210

    Article  CAS  PubMed  Google Scholar 

  • Salles G, Seymour JF, Offner F et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377(9759):42–51

    Article  CAS  PubMed  Google Scholar 

  • Schulz H, Bohlius J, Skoetz N et al (2007) Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin’s lymphoma (Review). Cochrane Database Syst Rev (4):CD003805

    Google Scholar 

  • Solal-Céligny P, Roy P, Colombat P et al (2004) Follicular lymphoma international prognostic index. Blood 104(5):1258–1265

    Article  PubMed  Google Scholar 

  • Vitolo U, Ladetto M, Boccomini C et al (2013) Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. J Clin Oncol 31(27):3351–3359

    Article  CAS  PubMed  Google Scholar 

  • Wilder RB, Jones D, Tucker SL, Fuller LM, Ha CS, McLaughlin P, Hess MA, Cabanillas F, Cox JD (2001) Long-term results with radiotherapy for stage I–II follicular lymphomas. Int J Radiat Oncol Biol Phys 51(5):1219–1227

    Article  CAS  PubMed  Google Scholar 

  • Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Vose JM (2009) Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s Lymphoma. J Clin Oncol 27(32):5404–5409

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mannheimer Onkologie Praxis, Q5, 14-22, 68161, Mannheim, Deutschland

    Manfred Hensel

  2. Innere Medizin V, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland

    Mathias Witzens-Harig

Authors
  1. Manfred Hensel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mathias Witzens-Harig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manfred Hensel .

Editor information

Editors and Affiliations

  1. II. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany

    Matthias Ebert

  2. II. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany

    Nicolai Härtel

  3. Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Thüringen, Germany

    Ulrich Wedding

Section Editor information

  1. Abteilung für Palliativmedizin, Universitätsklinikum Jena, Klinik für Innere Medizin II, Erlanger Allee 101, 07747, Jena, Deutschland

    Ulrich Wedding

Rights and permissions

Reprints and permissions

Copyright information

© 2017 © Springer-Verlag GmbH Deutschland

About this entry

Cite this entry

Hensel, M., Witzens-Harig, M. (2017). Niedrigmaligne Non-Hodgkin-Lymphome beim alten und geriatrischen Patienten. In: Ebert, M., Härtel, N., Wedding, U. (eds) Geriatrische Onkologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-49083-9_18-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-49083-9_18-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-49083-9

  • Online ISBN: 978-3-662-49083-9

  • eBook Packages: Springer Referenz Medizin

Publish with us

Policies and ethics

Search

Navigation